The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Biology and management of pancreatic cancer
Open accessAbstract
Pancreatic cancer continues to pose an enormous challenge to clinicians and cancer scientists. With a more affluent world the global incidence of pancreatic cancer is rising. For the first time significant advances are now being made into the management of the disease. There is a more sophisticated approach to palliative care and the centralisation of pancreatic cancer services is leading to greater tumour resection rates. Newer adjuvant modalities are also greatly increasing the 5 year survival rates. The molecular basis of pancreatic cancer is now better understood than ever before, leading to the development of new diagnostic approaches and the introduction of mechanistic based treatments. Technical advances in imaging and great improvements in conventional and molecular pathology have led to a deeper understanding of the pathological variables of the disease. This is now an important time for making big inroads into what still remains the most lethal of the common cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Hospital Volume and Surgical Mortality in the United States
Birkmeyer, J. D., Siewers, A. E., Finlayson, E. V. A., Stukel, T. A., Lucas, F. L., Batista, I., Welch, H. G., & Wennberg, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa012337 · Cited by 4,999
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Self-citationHingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Research works printed but not linked: 45
- Ko, 2005, Systemic therapy for pancreatic cancer, Semin Radiat Oncol, 15, 245, 10.1016/j.semradonc.2005.06.001 · doi:10.1016/j.semradonc.2005.06.001
- Friess, 1995, Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression, Clin Cancer Res, 1, 1413
- Barton, 1991, Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer, J Pathol, 163, 111, 10.1002/path.1711630206 · doi:10.1002/path.1711630206
- Anonymous, 2004, SWOG S0502: phase lll randomized study of gemcitabine with versus without cetuximab as first-line therapy in patients with locally advanced unresectable or metastatic adenocorcinoma of the pancreas, Clin Adv Hematol Oncol, 2, 201
- de Jonge, 2006, Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?, Eur J Cancer, 42, 1351, 10.1016/j.ejca.2006.02.013 · doi:10.1016/j.ejca.2006.02.013
- Zapatka, 2007, Basement membrane component laminin-5 is a target of the tumor suppressor Smad4, Oncogene, 25, 1417, 10.1038/sj.onc.1209918 · doi:10.1038/sj.onc.1209918
- Narita, 1984, Ataxia-telangiectasia with dysgerminoma of right ovary, papillary carcinoma of thyroid, and adenocarcinoma of pancreas, Cancer, 54, 1113, 10.1002/1097-0142(19840915)54:6<1113::AID-CNCR2820540632>3.0.CO;2-C · doi:10.1002/1097-0142(19840915)54:6<1113::aid-cncr2820540632>3.0.co;2-c
- Seket, 2003, Pancreatic acinar cell carcinoma in a patient with familial adenomatous polyposis, Gastroenterol Clin Biol, 27, 818
- Sudo, 2005, Development of an introductal papillary-mucinous neoplasm of the pancreas in a patient with familial adenomatous polyposis, Pancreas, 31, 428, 10.1097/01.mpa.0000183378.04295.27 · doi:10.1097/01.mpa.0000183378.04295.27
- Klöppel, 1996, World Health Organization international histological typing of tumors of the exocrine pancreas, 1
- Holen, 2002, Clinical characteristics and outcomes from on institutional series of acinar cell carcinoma of the pancreas and related tumors, J Clin Oncol, 20, 4673, 10.1200/JCO.2002.02.005 · doi:10.1200/jco.2002.02.005
- Seo, 2006, Solid-pseudopapillary tumor of the pancreas, J Clin Gastroenterol, 40, 919, 10.1097/01.mcg.0000225671.91722.10 · doi:10.1097/01.mcg.0000225671.91722.10
- Dhebri, 2004, Diagnosis, treatment and outcome of pancreatoblastoma, Pancreatology, 4, 441, 10.1159/000079823 · doi:10.1159/000079823
- Royal College of Pathologists, 2002, Standards and minimum datasets for reporting cancers. Minimum dataset for histopathological reporting of pancreatic, ampulla of vater and bile duct carcinoma
- Neoptolemos, 2005, Is endoscopic ultrasonography superior to multidetector CT for assessing pancreatic cancer?, Nat Clin Pract Oncol, 2, 78, 10.1038/ncponc0096 · doi:10.1038/ncponc0096
- Louhimo, 2004, Serum HCG beta and CA 72–4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer, Oncology, 66, 126, 10.1159/000077438 · doi:10.1159/000077438
- Ozkan, 2006, Significance of serum receptor-binding cancer antigen (RCAS) in pancreatic cancer and benign pancreatobiliaty diseases, Pancreatology, 6, 268, 10.1159/000092687 · doi:10.1159/000092687
- Hanninen, 2005, Magnetic resonance cholangiopancreatography: image quality, ductal morphology, and value of additional T2-and T1-weighted sequences for the assessment of suspected pancreatic cancer, Acta Radiol, 46, 117, 10.1080/02841850510020941 · doi:10.1080/02841850510020941
- Hanninen, 2002, Prospective evaluation of pancreatic tumours: accuracy of MR imaging with MR cholangiopancreotography and MR angiography, Radiology, 224, 34, 10.1148/radiol.2241010798 · doi:10.1148/radiol.2241010798
- Wittmann, 2006, Endoscopic ultrasound-guided tissue sampling by combined fine needle aspiration and trucut needle biopsy: a prospective study, Cytopathology, 17, 27, 10.1111/j.1365-2303.2006.00313.x · doi:10.1111/j.1365-2303.2006.00313.x
- Doran, 2004, Laparoscopy and laparoscopic ultrasound in the evaluation of pancreatic and periampullary tumours, Dig Surg, 21, 305, 10.1159/000080885 · doi:10.1159/000080885
- Connor, 2005, Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy, Dig Surg, 22, 80, 10.1159/000085297 · doi:10.1159/000085297
- Eguchi, 2006, Patients with pancreatic intraductal papillary mucinous neoplasms are at high risk of colorectal cancer development, Surgery, 139, 749, 10.1016/j.surg.2005.11.008 · doi:10.1016/j.surg.2005.11.008
- Suleyman Ozyalcin, 2004, Efficacy of coeliac plexus and splanchnic nerve blockades in body and tail located pancreatic cancer pain, Eur J Pain, 8, 539, 10.1016/j.ejpain.2004.01.001 · doi:10.1016/j.ejpain.2004.01.001
- Leksowski, 2001, Thoracoscopic splanchnicectomy for control of intractable pain due to advanced pancreatic cancer, Surg Endosc, 15, 129, 10.1007/s004640090009 · doi:10.1007/s004640090009
- Bruno, 1998, Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region, Gut, 42, 92, 10.1136/gut.42.1.92 · doi:10.1136/gut.42.1.92
- Prat, 1998, Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline, Gut, 42, 76, 10.1136/gut.42.1.76 · doi:10.1136/gut.42.1.76
- Kuriansky, 2000, Simultaneous laparoscopic biliary and retrocolic gastric bypass in patients with unresectable carcinoma of the pancreas, Surg Endosc, 14, 179, 10.1007/s004649900095 · doi:10.1007/s004649900095
- Cunningham, 2005, Phase lll randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer, Eur J Cancer, 3, (Suppl
- Smith, 2006, Capecitabine in carcinoma of the pancreas, Expert Opin Pharmacother, 7, 1633, 10.1517/14656566.7.12.1633 · doi:10.1517/14656566.7.12.1633
- Chauffert, 2006, Phase III trial comparing initial chemorodiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCD-SFRO study, J Clin Oncol, 4008, 10.1200/jco.2006.24.18_suppl.4008 · doi:10.1200/jco.2006.24.18_suppl.4008
- Genentech, Phase III study of Avastin in odvanced pancreatic cancer does not meet primary endpoint
- Roche, Clinical trial protocol registry and results database
- National Cancer Institute, GV1001 and gemcitabine in sequential combination to gemcitabine monotherapy in pancreatic cancer
- National Cancer Institute, Phase III randomized study of chemoimmunotherapy comprising gemcitabine hydrochloride and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer
- Settmacher, 2004, Reconstruction of visceral orteries with homografts in excision of the pancreas, Chirurg, 75, 1199, 10.1007/s00104-004-0899-4 · doi:10.1007/s00104-004-0899-4
- Saleh, 2002, Preoperative endoscopic stent placement before pancreaticoduodenectomy: a meta-analysis of the effect on morbidity and mortality, Gastrointest Endosc, 56, 529, 10.1016/S0016-5107(02)70438-0 · doi:10.1016/s0016-5107(02)70438-0
- Imamura, 2004, A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer, Surgery, 136, 1003, 10.1016/j.surg.2004.04.030 · doi:10.1016/j.surg.2004.04.030
- McKay, 2006, Meta-analysis of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy, Br J Surg, 93, 929, 10.1002/bjs.5407 · doi:10.1002/bjs.5407
- Winter, 2006, Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial, J Gastrointest Surg, 10, 1280, 10.1016/j.gassur.2006.07.020 · doi:10.1016/j.gassur.2006.07.020
- Lin, 1999, Prospective randomized comparison between pylorus-preserving and standard pancreatoduodenectomy, Br J Surg, 86, 603, 10.1046/j.1365-2168.1999.01074.x · doi:10.1046/j.1365-2168.1999.01074.x
- Takada, 2002, Is postoperative adjuvant chemotherapy useful for gall-bladder carcinoma?, Cancer, 95, 1685
- Kosuge, 2006, A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer, Jpn J Clin Oncol, 36, 159, 10.1093/jjco/hyi234 · doi:10.1093/jjco/hyi234
- Stocken, 2005, Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer, Br J Cancer, 92, 1372, 10.1038/sj.bjc.6602513 · doi:10.1038/sj.bjc.6602513
- Regine, 2006, RichRTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma, J Clin Oncol, 4007, 10.1200/jco.2006.24.18_suppl.4007 · doi:10.1200/jco.2006.24.18_suppl.4007
Cited by
Huang, L., Holtzinger, A., Jagan, I., BeGora, M., Lohse, I., Ngai, N., Nostro, C., Wang, R., Muthuswamy, L. B., Crawford, H. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3973 · Cited by 740
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i2.173 · Cited by 472
Chemophototherapy: An Emerging Treatment Option for Solid Tumors
Luo, D., Carter, K. A., Miranda, D., & Lovell, J. F. (2017) · Advanced Science · doi:10.1002/advs.201600106 · Cited by 436
Mazur, P. K., Herner, A., Mello, S. S., Wirth, M., Hausmann, S., Sánchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S. A., Vangala, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3952 · Cited by 397
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report
Duffy, M. J., Sturgeon, C., Lamerz, R., Haglund, C., Holubec, V. L., Klapdor, R., Nicolini, A., Topolcan, O., & Heinemann, V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp332 · Cited by 381
Metadata
- Authors
- Ghaneh, P., Costello, E., & Neoptolemos, J. P.
- Venue
- Postgraduate Medical Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-09-01
- Volume
- 84
- Issue
- 995
- Pages
- 478-497
- ISSN
- 0032-5473 (ISSN-L)
- 1469-0756
- OpenAlex
- W2133667676
- Cited by
- 418
- References
- 195
- FWCI
- 14.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biology and management of pancreatic cancer. https://app.cochat.ai/papers/10.1136/gut.2006.103333
- The paper
- Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2008). Biology and management of pancreatic cancer. Postgraduate Medical Journal. https://doi.org/10.1136/gut.2006.103333
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.